Search Results

You are looking at 1 - 10 of 903 items for :

  • "risk factor" x
  • Refine by Access: Content accessible to Me x
Clear All
Full access

External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving Chemotherapy

Mostafa R. Mohamed, Kah Poh Loh, Supriya G. Mohile, Michael Sohn, Tracy Webb, Megan Wells, Sule Yilmaz, Rachael Tylock, Eva Culakova, Allison Magnuson, Can-Lan Sun, James Bearden, Judith O. Hopkins, Bryan A. Faller, and Heidi D. Klepin

decline and loss of independence. 3 , 4 Moreover, hospitalization is associated with increased healthcare expenses and a significant financial burden for older adults with cancer and their families. 5 – 7 Identification of validated risk factors for

Full access

Risk Factors for Development of Hypocalcemia in Patients With Cancer Treated With Bone-Modifying Agents

Paul S. White, Michael Dennis, Eric A. Jones, Janice M. Weinberg, and Shayna Sarosiek

-institution retrospective study, we sought to identify the prevalence of hypocalcemia and determine the risk factors for development of hypocalcemia in a diverse, multiracial population of patients with cancer receiving treatment with BMAs. Patients and Methods We performed

Full access

Risk Factors for Early Death After Rituximab-Based Immunochemotherapy in Older Patients With Diffuse Large B-Cell Lymphoma

Adam J. Olszewski, Kalyan C. Mantripragada, and Jorge J. Castillo

risk factors for death and hospitalization during the first month of rituximab-based immunochemotherapy using population-based data from Medicare beneficiaries. Patients and Methods Data Source and Cohort Selection This study used

Full access

Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Michael B. Streiff, Bjorn Holmstrom, Dana Angelini, Aneel Ashrani, Amro Elshoury, John Fanikos, Kleber Yotsumoto Fertrin, Annemarie E. Fogerty, Shuwei Gao, Samuel Z. Goldhaber, Krishna Gundabolu, Ibrahim Ibrahim, Eric Kraut, Andrew D. Leavitt, Alfred Lee, Jason T. Lee, Ming Lim, Janelle Mann, Karlyn Martin, Brandon McMahon, John Moriarty, Colleen Morton, Thomas L. Ortel, Rita Paschal, Jordan Schaefer, Sanford Shattil, Tanya Siddiqi, Deepak Sudheendra, Eliot Williams, Liz Hollinger, and Mai Q. Nguyen

update of the NCCN Guidelines are available at NCCN.org. VTE Risk Assessment in Patients With Cancer VTE risk factors in patients with cancer can be grouped into 3 general categories: patient-related factors, cancer-related factors, and treatment

Full access

Identification of Risk Factors for Chemotherapy-Related 30-Day Readmissions

Jeremy Lund, Angela Pearson, and Georgia Keriazes

call for a multidisciplinary, coordinated effort to identify potential risk factors for readmission. 2 With the recent changes to repayment structures by CMS for selected diagnoses and the prospect of that list growing, it is imperative for

Full access

Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response

Fangwen Zou, Hamzah Abu-Sbeih, Weijie Ma, Yuanzun Peng, Wei Qiao, Jianbo Wang, Amishi Y. Shah, Isabella C. Glitza Oliva, Sarina A. Piha-Paul, John A. Thompson, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang

the risk factors for chronic IMDC or its effects on the overall cancer outcome. We attempted to bridge this knowledge gap in a retrospective study of patients with advanced malignancies at The University of Texas MD Anderson Cancer Center (MDACC

Full access

Clinical and Genetic Risk Factors for Adverse Metabolic Outcomes in North American Testicular Cancer Survivors

Mohammad Abu Zaid, Wambui G. Gathirua-Mwangi, Chunkit Fung, Patrick O. Monahan, Omar El-Charif, Annalynn M. Williams, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Ryan Cook, Sandra K. Althouse, Shirin Ardeshir-Rouhani-Fard, Paul C. Dinh Jr, Howard D. Sesso, Lawrence H. Einhorn, Sophie D. Fossa, Lois B. Travis, and for the Platinum Study Group

disease (CVD) compared with controls. 8 – 13 In the general population, metabolic syndrome (MetS) is a major risk factor for CVD. 14 MetS is a constellation of interrelated CVD risk factors, including insulin resistance, hypertension, elevated

Full access

Importance of Risk Factors for Febrile Neutropenia Among Patients Receiving Chemotherapy Regimens Not Classified as High-Risk in Guidelines for Myeloid Growth Factor Use

Derek Weycker, Xiaoyan Li, Rich Barron, Hongsheng Wu, P.K. Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani K. Mhatre, and Gary H. Lyman

-stimulating factor (CSF) when risk, based on the chemotherapy regimen and patient risk factors, is “high” (>20%) (to view the most recent version of these guidelines, visit NCCN.org ). For patients whose risk is high based on the chemotherapy regimen alone, the

Full access

Risk Factors Associated With Distress Among Postoperative Patients in an Academic Gynecologic Oncology Practice

Maya E. Gross, Janelle N. Sobecki, Chan Park, Menggang Yu, and Sumer K. Wallace

burgeoning body of evidence surrounding distress in gynecologic cancer, gaps in knowledge exist regarding both risk factors for increased distress and optimal timing of collection. Many existing studies focus on survivors of gynecologic cancers as opposed to

Full access

Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221

Ciao-Sin Chen, Gary Zirpoli, William E. Barlow, G. Thomas Budd, Bryan McKiver, Lajos Pusztai, Gabriel N. Hortobagyi, Kathy S. Albain, M. Imad Damaj, Andrew K. Godwin, Alastair Thompson, N. Lynn Henry, Christine B. Ambrosone, Kathleen A. Stringer, and Daniel L. Hertz

factors, such as age, race, and genetics, and potentially though not easily modifiable risk factors, such as diabetes, sedentary lifestyle, and high systemic paclitaxel exposure. 10 Several retrospective studies suggested that patients with lower